Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Nov 15, 2020; 12(11): 1296-1310
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1296
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1296
Total | PTR | No PTR | P value | |
Age | 0.0065 | |||
n | 466 | 313 | 153 | |
Mean (std) | 64.0 (11.6) | 63.0 (11.1) | 66.1 (12.4) | |
Median [min-max] | 65.0 (24.0-92.0) | 63.0 (29.0-90.0) | 67.0 (24.0-92.0) | |
Gender | 0.9563 | |||
Male | 255 (54.7%) | 171 (54.6%) | 84 (54.9%) | |
Female | 211 (45.3%) | 142 (45.4%) | 69 (45.1%) | |
Primary tumor location | 0.0010 | |||
Left colon + sigmoid | 203 (43.6%) | 153 (48.9%) | 50 (32.7%) | |
Right colon + transverse colon | 174 (37.3%) | 112 (35.8%) | 62 (40.5%) | |
Rectum | 89 (19.1%) | 48 (15.3%) | 41 (26.8%) | |
PS | 0.0296 | |||
0-1 | 300 (83.6%) | 202 (86.7%) | 98 (77.8%) | |
2-4 | 59 (16.4%) | 31 (13.3%) | 28 (22.2%) | |
Missing values | 107 | 80 | 27 | |
Number of metastatic sites | 0.1080 | |||
1 | 283 (60.7%) | 200 (63.9%) | 83 (54.2%) | |
2 | 133 (28.5%) | 84 (26.8%) | 49 (32.0%) | |
> 2 | 50 (10.7%) | 29 (9.3%) | 21 (13.7%) | |
Metastatic sites | ||||
Liver | 0.9689 | |||
No | 89 (19.2%) | 60 (19.2%) | 29 (19.1%) | |
Yes | 375 (80.8%) | 252 (80.8%) | 123 (80.9%) | |
Missing values | 2 | 1 | 1 | |
Lung | 0.0206 | |||
No | 342 (73.9%) | 240 (77.2%) | 102 (67.1%) | |
Yes | 121 (26.1%) | 71 (22.8%) | 50 (32.9%) | |
Missing values | 3 | 2 | 1 | |
Peritoneum | 0.8377 | |||
No | 356 (76.9%) | 240 (77.2%) | 116 (76.3%) | |
Yes | 107 (23.1%) | 71 (22.8%) | 36 (23.7%) | |
Missing values | 3 | 2 | 1 | |
Other | 0.2531 | |||
No | 361 (78.1%) | 247 (79.7%) | 114 (75.0%) | |
Yes | 101 (21.9%) | 63 (20.3%) | 38 (25.0%) | |
Missing values | 4 | 3 | 1 | |
KRAS mutation | 0.5956 | |||
No | 202 (56.7%) | 143 (57.7%) | 59 (54.6%) | |
Yes | 154 (43.3%) | 105 (42.3%) | 49 (45.4%) | |
Missing values | 110 | 65 | 45 | |
BRAF mutation | 0.3218 | |||
No | 265 (90.1%) | 188 (91.3%) | 77 (87.5%) | |
Yes | 29 (9.9%) | 18 (8.7%) | 11 (12.5%) | |
Missing values | 172 | 107 | 65 | |
CEA | 0.0002 | |||
≤ 200 | 251 (68.6%) | 177 (75.3%) | 74 (56.5%) | |
> 200 | 115 (31.4%) | 58 (24.7%) | 57 (43.5%) | |
Missing values | 100 | 78 | 22 | |
LDH | < 0.0001 | |||
≤ 254 | 175 (53.2%) | 130 (62.2%) | 45 (37.5%) | |
> 254 | 154 (46.8%) | 79 (37.8%) | 75 (62.5%) | |
Missing values | 137 | 104 | 33 | |
Leukocytes > 10000 | 0.0014 | |||
No | 256 (70.9%) | 175 (76.8%) | 81 (60.9%) | |
Yes | 105 (29.1%) | 53 (23.2%) | 52 (39.1%) | |
Missing values | 105 | 85 | 20 | |
Alkaline phosphatase > 300 | 0.0008 | |||
No | 261 (77.9%) | 179 (83.6%) | 82 (67.8%) | |
Yes | 74 (22.1%) | 35 (16.4%) | 39 (32.2%) | |
Missing values | 131 | 99 | 32 | |
Oxaliplatin | 0.3478 | |||
No | 35 (7.5%) | 21 (6.7%) | 14 (9.2%) | |
Yes | 431 (92.5%) | 292 (93.3%) | 139 (90.8%) | |
5 FU or capecitabine | 1.0000 | |||
No | 3 (0.6%) | 2 (0.6%) | 1 (0.7%) | |
Yes | 463 (99.4%) | 311 (99.4%) | 152 (99.3%) | |
Irinotecan | 0.1278 | |||
No | 105 (22.6%) | 64 (20.5%) | 41 (26.8%) | |
Yes | 360 (77.4%) | 248 (79.5%) | 112 (73.2%) | |
Missing values | 1 | 1 | 0 | |
Bevacizumab | 0.1978 | |||
No | 150 (32.4%) | 95 (30.4%) | 55 (36.4%) | |
Yes | 313 (67.6%) | 217 (69.6%) | 96 (63.6%) | |
Missing values | 3 | 1 | 2 | |
EGFR inhibitors | 0.2681 | |||
No | 267 (57.5%) | 174 (55.8%) | 93 (61.2%) | |
Yes | 197 (42.5%) | 138 (44.2%) | 59 (38.8%) | |
Missing values | 2 | 1 | 1 | |
1st line chemotherapy regimen | 0.7568 | |||
Mono-chemotherapy | 48 (10.4%) | 32 (10.3%) | 16 (10.5%) | |
Bi-chemotherapy | 326 (70.6%) | 216 (69.7%) | 110 (72.4%) | |
Tri- chemotherapy | 88 (19.0%) | 62 (20.0%) | 26 (17.1%) | |
Missing values | 4 | 3 | 1 | |
Lung or Liver surgery or radio-frequency | < 0.0001 | |||
No | 326 (70.4%) | 178 (57.4%) | 148 (96.7%) | |
Yes | 137 (29.6%) | 132 (42.6%) | 5 (3.3%) | |
Missing values | 3 | 3 | 0 |
HR | 95%CI | P value | ||
Age | n = 466 | 0.0714 | ||
> 65 yr vs ≤ 65 yr | 1.209 | [0.984-1.485] | ||
Gender | n = 466 | 0.3701 | ||
Female vs male | 1.099 | [0.894-1.350] | ||
Tumor location | n = 466 | 0.0022 | ||
Rectum vs left colon + sigmoid | 1.019 | [0.767-1.355] | ||
Right colon + transverse colon vs Left colon + sigmoid | 1.464 | [1.16-1.841] | ||
Number of metastatic sites | n = 466 | 0.0035 | ||
2 vs 1 | 1.219 | [0.965-1.539] | ||
> 2 vs 1 | 1.749 | [1.245-2.455] | ||
Number of metastatic sites | n = 466 | 0.0084 | ||
≥ 2 vs 1 | 1.328 | [1.076-1.641] | ||
Liver metastases | n = 464 | 0.8836 | ||
Yes vs No | 1.020 | [0.782-1.330] | ||
Lung metastases | n = 463 | 0.6435 | ||
Yes vs No | 1.057 | [0.835-1.338] | ||
Peritoneum metastases | n = 463 | 0.0619 | ||
Yes vs No | 1.260 | [0.989-1.606] | ||
Other metastases | n = 462 | 0.0114 | ||
Yes vs No | 1.377 | [1.075-1.765] | ||
KRAS mutation | n = 356 | 0.0696 | ||
Yes vs No | 1.256 | [0.982-1.606] | ||
BRAF mutation | n = 294 | < 0.0001 | ||
Yes vs No | 2.276 | [1.511-3.429] | ||
CEA | n = 366 | < 0.0001 | ||
> 200 vs ≤ 200 | 1.654 | [1.290-2.120] | ||
LDH | n = 329 | < 0.0001 | ||
> 254 vs ≤ 254 | 2.022 | [1.574-2.596] | ||
Leukocytes > 10000 | n = 361 | 0.0016 | ||
Yes vs No | 1.506 | [1.168-1.941] | ||
Alkaline phosphatase > 300 | n = 335 | < 0.0001 | ||
Yes vs No | 2.272 | [1.713-3.014] | ||
PTR | n = 466 | < 0.0001 | ||
Yes vs No | 0.313 | [0.250-0.392] | ||
Oxaliplatin | n = 466 | < 0.0001 | ||
Yes vs No | 0.361 | [0.248-0.524] | ||
Irinotecan | n = 465 | 0.112 | ||
Yes vs No | 0.807 | [0.619-1.051] | ||
5 FU or Capecitabine | n = 466 | 0.2869 | ||
Yes vs No | 0.539 | [0.173-1.682] | ||
Bevacizumab | n = 463 | 0.0117 | ||
Yes vs No | 0.750 | [0.599-0.938] | ||
EGFR inhibitors | n = 464 | 0.0129 | ||
Yes vs No | 0.769 | [0.625-0.946] | ||
1rst line chemotherapy regimen | n = 462 | 0.0080 | ||
Bi-chemotherapy vs Mono-chemotherapy | 0.682 | [0.496-0.937] | ||
Tri-chemotherapy vs Mono-chemotherapy | 0.543 | [0.368-0.799] | ||
Lung or liver surgery or radio-frequency | n = 463 | < 0.0001 | ||
Yes vs No | 0.302 | [0.235-0.388] |
- Citation: Tharin Z, Blanc J, Charifi Alaoui I, Bertaut A, Ghiringhelli F. Influence of primary tumor location and resection on survival in metastatic colorectal cancer. World J Gastrointest Oncol 2020; 12(11): 1296-1310
- URL: https://www.wjgnet.com/1948-5204/full/v12/i11/1296.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i11.1296